In a clinical trial involving 572 NSCLC patients with high PD-L1 expression and wild-type EGFR and ALK, the Atezolizumab group had a significantly higher median overall survival than the chemotherapy group (7.1 months; p = 0.01) [106]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.